Cytotoxic T lymphocyte responses to a liposome-adjuvanted influenza A virus vaccine in the elderly
- PMID: 7561189
- DOI: 10.1093/infdis/172.4.1103
Cytotoxic T lymphocyte responses to a liposome-adjuvanted influenza A virus vaccine in the elderly
Abstract
This randomized double-blind study evaluated cytotoxic T lymphocyte (CTL) responses of elderly volunteers after parenteral immunization with either liposome-adjuvanted (n = 23) or control subvirion (n = 26) vaccine containing detergent-split influenza A/Taiwan/1/86 (H1N1) virus. Peripheral blood mononuclear cells obtained 0, 2, and 12 weeks after vaccination were stimulated in vitro with influenza A (H1N1) virus-infected autologous cells and then assayed for influenza virus-specific cytotoxicity using autologous virus-infected target cells. CTL responses to vaccination exhibited influenza A virus heterosubtypic cross-reactivity and were mediated primarily by CD8+ effector cells. Anti-influenza virus CTL activity was enhanced to a significantly greater extent by the liposome vaccine than by the control subvirion vaccine. It remains to be established whether the advantage of a liposomal formulation in terms of an improved CTL response is relevant to vaccine protective efficacy.
Similar articles
-
Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults.Mech Ageing Dev. 1997 Feb;93(1-3):179-88. doi: 10.1016/s0047-6374(96)01809-x. Mech Ageing Dev. 1997. PMID: 9089582 Clinical Trial.
-
Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).Virology. 1999 Jul 5;259(2):256-61. doi: 10.1006/viro.1999.9765. Virology. 1999. PMID: 10388649 Clinical Trial.
-
In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant.Vaccine. 1995 Oct;13(14):1330-5. doi: 10.1016/0264-410x(95)00002-i. Vaccine. 1995. PMID: 8585289 Clinical Trial.
-
Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine.Microbiol Immunol. 2011 Jan;55(1):19-27. doi: 10.1111/j.1348-0421.2010.00273.x. Microbiol Immunol. 2011. PMID: 21175770 Review.
-
Development of a universal CTL-based vaccine for influenza.Bioengineered. 2013 Nov-Dec;4(6):374-8. doi: 10.4161/bioe.23573. Epub 2013 Jan 21. Bioengineered. 2013. PMID: 23337287 Free PMC article. Review.
Cited by
-
Immunogenetic factors associated with severe respiratory illness caused by zoonotic H1N1 and H5N1 influenza viruses.Clin Dev Immunol. 2012;2012:797180. doi: 10.1155/2012/797180. Epub 2011 Nov 3. Clin Dev Immunol. 2012. PMID: 22110538 Free PMC article. Review.
-
Adjuvanted nanoliposomes displaying six hemagglutinins and neuraminidases as an influenza virus vaccine.Cell Rep Med. 2024 Mar 19;5(3):101433. doi: 10.1016/j.xcrm.2024.101433. Epub 2024 Feb 23. Cell Rep Med. 2024. PMID: 38401547 Free PMC article.
-
Adjuvanted influenza vaccines.Hum Vaccin Immunother. 2018 Mar 4;14(3):550-564. doi: 10.1080/21645515.2017.1415684. Epub 2018 Jan 25. Hum Vaccin Immunother. 2018. PMID: 29232151 Free PMC article. Review.
-
Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene.Infect Immun. 1999 Dec;67(12):6358-63. doi: 10.1128/IAI.67.12.6358-6363.1999. Infect Immun. 1999. PMID: 10569750 Free PMC article.
-
Immunodeficiency of aging.Drugs Aging. 1997 Nov;11(5):374-97. doi: 10.2165/00002512-199711050-00005. Drugs Aging. 1997. PMID: 9359024 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials